News / BioPorto receives Frost & Sullivan Award

BioPorto receives Frost & Sullivan Award

Frost & Sullivan awards Product Leadership Award to BioPorto Diagnostics for acute kidney injury (AKI) diagnostics

BioPorto Diagnostics' development and marketing of The NGAL Test can reduce the spread and worsening of chronic kidney disease in patients with acute kidney injury.

Frost & Sullivan has recently completed an analysis of  the market for the diagnosis of patients with acute kidney injury and on that  basis acclaimed BioPorto and the NGAL test as a leader in the diagnosis of acute kidney injury.

BioPorto Diagnostics had identified an early biomarker known  as neutrophil gelatinase-associated lipocalin (NGAL) to determine the risk of  developing acute kidney injury or show progression of the condition significantly earlier (up to 48-72 hours) than other diagnostic tests in standard use today by hospitals and clinics. Using The NGAL Test can reduce the risks created by acute kidney injury in patients following, for example, heart surgery or a kidney transplant.

Frost & Sullivan highlights that The NGAL test in particular, because unlike competing assays it is developed to diagnose acute kidney injury in both blood and urine tests, and the NGAL Test is the only assay that can be used in a wide range of analytical instruments. This makes it easier for hospitals and clinics to implement a diagnostic test for acute kidney injury and thus achieve faster diagnosis.

BioPorto Diagnostics' CEO, Peter Morch Eriksen, is pleased and proud on behalf of the company receiving the award.

"Our mission is to help improve the diagnosis of patients at risk of developing acute kidney injury and improve the treatment of patients with acute kidney injury. Acute kidney injury has evolved to become a global burden, with millions affected by it and causing a proportional number of deaths each year. In most cases, acute kidney injury is detected too late and there is an acute and clear need for early diagnosis, so the disease can be prevented or treated quickly. "

"In the past few years ​​several clinical studies have shown NGAL to be a biomarker that may help to save lives and improve the treatment of patients with AKI or at risk of developing AKI. Frost &
Sullivan's acclaim emphasizes that the NGAL Test is a product that can satisfy unmet needs in the health sector and thus make a difference to patients and doctors worldwide", added Mr. Eriksen.

Download the Frost & Sullivan report here.

For further information, please contact:

Peter Mørch Eriksen, CEO

Telephone 45 29 00 00, mail investor@bioporto.com